What Can Korean Pharma Do Right To Build R&D, Alliances?
This article was originally published in PharmAsia News
What is an ideal R&D business model for the South Korean pharma industry and what are some of the key factors that could lead to successful novel research? At a recent meeting in Seoul, executives from leading domestic pharma companies including Yuhan and Hanmi shared their views and experience on how to develop valuable assets and seal successful international licensing deals.
You may also be interested in...
Helped by a hefty financing earlier this year, Bukwang subsidiary Contera Pharma is poised to speed ongoing multinational Phase II trials with its lead asset for Parkinson’s-associated dyskinesia by hiring CNS experts as new top executives, as the Korean firm looks to take it public in ground-breaking move.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
After completing a major financing last year, expectations are rising at D&D Pharmatech as it progresses large-scale, Phase II global trials with its neuroinflammation pipeline for Parkinson’s and Alzheimer’s disease. Its CEO talks to Scrip about what's in store for the South Korean biotech.